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Abstract
Summary This first-in-human study of AGN1 LOEP demonstrated that this minimally-invasive treatment durably increased
aBMD in femurs of osteoporotic postmenopausal women. AGN1 resorption was coupled with new bone formation by 12 weeks
and that new bone was maintained for at least 5–7 years resulting in substantially increased FEA-estimated femoral strength.
Introduction This first-in-human study evaluated feasibility, safety, and in vivo response to treating proximal femurs of post-
menopausal osteoporotic women with a minimally-invasive local osteo-enhancement procedure (LOEP) to inject a resorbable
triphasic osteoconductive implant material (AGN1).
Methods This prospective cohort study enrolled 12 postmenopausal osteoporotic (femoral neck T-score ≤ − 2.5) women aged 56
to 89 years. AGN1 LOEPwas performed on left femurs; right femurs were untreated controls. Subjects were followed-up for 5–7
years. Outcomes included adverse events, proximal femur areal bone mineral density (aBMD), AGN1 resorption, and replace-
ment with bone by X-ray and CT, and finite element analysis (FEA) estimated hip strength.
Results Baseline treated and control femoral neck aBMD was equivalent. Treated femoral neck aBMD increased by 68 ± 22%,
59 ± 24%, and 58 ± 27% over control at 12 and 24 weeks and 5–7 years, respectively (p < 0.001, all time points). Using
conservative assumptions, FEA-estimated femoral strength increased by 41%, 37%, and 22% at 12 and 24 weeks and 5–7 years,
respectively (p < 0.01, all time points). Qualitative analysis of X-ray and CT scans demonstrated that AGN1 resorption and
replacement with bone was nearly complete by 24 weeks. By 5–7 years, AGN1 appeared to be fully resorbed and replaced with
bone integrated with surrounding trabecular and cortical bone. No procedure- or device-related serious adverse events (SAEs)
occurred.
Conclusions Treating femurs of postmenopausal osteoporotic women with AGN1 LOEP results in a rapid, durable increase in
aBMD and femoral strength. These results support the use and further clinical study of this approach in osteoporotic patients at
high risk of hip fracture.
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00198-019-05230-0) contains supplementary
material, which is available to authorized users.
* R.S. Hill
rhill@agnovos.com
1 AgNovos Healthcare LLC, Rockville, MD, USA
2 Bioclinica-Synarc, Inc., Hamburg, Germany
3 FAU University Erlangen-Nürnberg and Universitätsklinikum
Erlangen, Erlangen, Germany
4 University of California San Francisco, San Francisco, CA, USA
5 Bioclinica-Synarc, Inc., Newark, CA, USA
6 O.N. Diagnostics, Berkeley, CA, USA
7 University of California Berkeley, Berkley, CA, USA
8 Beth Israel Deaconess Medical Center and Harvard Medical School,
Boston, MA, USA
9 Mansfield Orthopedics, Morrisville, VT, USA
https://doi.org/10.1007/s00198-019-05230-0
Osteoporosis International (2020) 31:921–929
/Published online: 4December 2019
Keywords Bonemineral density . Femoral strength . Finite element analysis .Hip fracture .Local osteo-enhancement procedure .
LOEP . Osteoporosis . proximal femur
Introduction
Fragility fractures of the hip are associated with significant
morbidity and mortality, and represent a significant burden
on affected individuals, families, and healthcare systems
[1–3]. Although multiple factors contribute to hip fracture
risk, a key factor is osteoporosis, a disease characterized by
bone loss [4, 5]. By restoring bone loss due to osteoporosis,
the weakened area is strengthened, resulting in increased force
required to produce a fracture, thereby reducing fracture risk.
Hip bone mineral density (BMD) is a major determinant of
femoral bone strength explaining an estimated 70% of the
strength [6]. It is particularly predictive of hip fracture risk
versus fracture risk in other anatomical sites [7–9]. Other fac-
tors including age, family history, previous fractures, exces-
sive drinking, visual acuity, falls, and dementia also play a role
in determining fracture risk [10].
Despite current treatment options for osteoporosis, significant
fracture risk remains, suggesting a need for new therapies [11].
Pharmacologic therapies that increase bone mass and reduce
fracture risk in osteoporotic patients exist, but only a small pro-
portion of patients are prescribed these therapies and when they
are prescribed, compliance is low [12]. More importantly,
existing therapies have not been shown to reduce fracture risk
during the early stages of therapy, taking 9–18 months to signif-
icantly reduce hip fracture risk [11]. In patients with a recent hip
fracture, the risk of a second contralateral hip fracture is signifi-
cantly elevated in the months after the first fracture, and remains
elevated for years [13]. There is a growing global consensus
among leading clinicians that minimally-invasive surgical ap-
proaches intended to complement current therapies warrant con-
sideration to further reduce risk of fragility fracture in patients at
elevated risk [11, 14]. The recently published guidance on diag-
nosis and management of postmenopausal osteoporosis in wom-
en by the International Osteoporosis Foundation (IOF) and
European Society of Clinical and Economic Aspects of
Osteoporosis (ESCEO) included a local osteo-enhancement pro-
cedure (LOEP) as a treatment option [15].
Prior investigations of surgical approaches to strengthen the
proximal femur include the use of polymethyl methacrylate
(PMMA) and prophylactic pinning or nailing [16, 17].
However, these non-biological approaches involve the perma-
nent placement of inert materials that create a mismatch in elastic
moduli with the surrounding bone, whichmay alter normal load-
transmission pathways.
In this study, we investigated the AGN1 local osteo-
enhancement procedure (LOEP), a minimally-invasive surgi-
cal approach to prepare an enhancement site, the area where
new bone is desired within a local bony region weakened by
osteoporotic bone loss, and to fill that site with a triphasic,
resorbable, calcium-based implant material. This approach in-
volves a single treatment that provides immediate strengthen-
ing [18], followed by resorption of the implant material and
replacement with new bone.
This proof-of-concept study was designed to evaluate
AGN1 LOEP treatment in postmenopausal women with oste-
oporosis, a population at elevated risk of fracture due to bone
loss. The study was designed to determine: 1) the initial and
long-term safety of treating the proximal femur using AGN1
LOEP, 2) the rate and extent of resorption and replacement of
AGN1with new bone in the proximal femur, and 3) initial and
long-term changes in proximal femoral BMD and strength
following AGN1 implantation.
Methods
A prospective, single-cohort study of AGN1 LOEP was con-
ducted at a community-based hospital (Copley Hospital in
Morrisville, VT, U.S.A.) between 2009 and 2016. Subjects
were recruited from patients diagnosed with osteoporosis
based on DXA scans completed at the Copley Hospital.
Enrolled subjects were treated from 2009 to 2010 and were
followed-up regularly for 24 months, with an additional
follow-up visit 5–7 years after treatment in 2016, with an
average follow-up of 6 years. The study was IRB-approved
by the Western Institutional Review Board and all subjects
provided written informed consent.
The study enrolled 12 Caucasian postmenopausal women.
Inclusion criteria included age ≥ 55 years and femoral neck
aBMD T-score ≤ − 2.5 assessed by dual-energy X-ray absorpti-
ometry (DXA, Hologic Delphi C). Note that one subject was
admitted to the study with an aBMD T-score > − 2.5. Subjects
were excluded if they suffered a previous hip fracture, had cre-
atinine > 2.0 mg/100 mL, or a GFR < 30 mL/min. No additional
blood analyses or biochemical markers were measured as part of
the study. Subjects’ pharmacological management of osteoporo-
sis was not altered as a result of participating in the study. At
enrollment, 6 subjects had been prescribed bisphosphonates and
1 subject had been prescribed hormone replacement therapy
(Table 1). At the extension follow-up visit, 2 of the subjects
had prescriptions for bisphosphonate treatment.
All study subjects received AGN1 LOEP treatment to the left
proximal femur while no procedural treatment was performed on
the right contralateral proximal femur, which served as a pair-
wise untreated control. All procedures were completed by the
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two study investigators (BH, JGH), both orthopedic surgeons, at
the Copley Hospital. All self-reported medical history data were
verified through a medical record review.
AGN1 LOEPwas performed with the subject positioned on a
fracture table under anesthesia as recommended by the anesthe-
siologist. A 1 cm skin incision was made to gain access to the
proximal lateral femoral cortex just below the greater trochanter,
and a 2.5mmguide pinwas advanced centrally to the apex of the
femoral neck under fluoroscopic guidance (Fig. 1a). A 5.3 mm
cannulated drill was advanced over the guide pin to the
subcapital femoral epiphyseal scar to access the enhancement
site (Fig. 1b). The enhancement site was gently debrided and
the site was irrigated with sterile saline and then aspirated to
remove fat and other loose non-structural elements (Fig. 1c).
The prepared AGN1 implant material was injected starting at
the apex of the enhancement site (Fig. 1d) using low pressure
under fluoroscopic guidance to fill the enhancement site. The
injected AGN1, average implant volume 19 ± 2 cc (range 15 to
22 cc), completely sets within 60 min after mixing. Following
recovery from anesthesia, subjects were fully weight-bearing
within 4 h of the procedure. The skin incision healed rapidly in
all subjects and the cortical access portal was healed in all 10
subjects as determined by CT imaging at the 5–7 year extension.
The study’s primary outcome was comparison of the post-
injection femoral neck areal bone mineral density (aBMD,
g/cm2 by DXA) versus the untreated contralateral femur with
a secondary analysis comparing it to pre-treatment baseline
values. aBMD values were equated to a T-score as appropriate
using the NHANES 1998 reference values. DXA scans of
both hips were taken at pre-treatment baseline and at 1, 6,
12, 18, and 24 weeks; 12, 18, and 24 months; and at the
extension follow-up visit that occurred at an average of 6 years
post-treatment. Extension aBMDwas assessed by BioClinica.
All other time points were assessed at Copley Hospital by a
Hologic technician.
Anterior–posterior and lateral hip X-rays (pre-treatment, 6,
12, and 24weeks, and 6 years post-treatment) and bilateral hip
CTs (pre-treatment, 12, and 24 weeks, CT Model Phillips
Brilliance 16P scanner; and 6 years post-treatment, CT
Model Siemens SOMATOM Definition AS scanner) were
also acquired to qualitatively examine AGN1 resorption and
to evaluate the extent of new bone formation.
For all subjects, axial and coronal planes and sometimes
sagittal reformations of CT scans of all treatment visits were
simultaneously viewed side-by-side. The approximate amount
of high density (opaque) AGN1 remaining, in percentages,
was judged from the marginated boundaries between the pe-
ripheral trabecular marrow space, an intermediate density
zone of newly mineralized tissue and the higher density inner
zone of unresorbed AGN1. All CT images were reviewed
centrally on the same equipment to ensure consistency.
Femoral strength was estimated in simulated sideway fall
loading condition using subject-specific nonlinear finite ele-
ment analysis (FEA), as previously described [19]. Briefly,
CT scans of the treated and untreated contralateral femurs
were analyzed at pre-treatment, 12 and 24 weeks, and 6 years
post-treatment using VirtuOst Version 1.2 (O.N. Diagnostics).
VirtuOst is cleared by the FDA to measure bone strength,
assess fracture risk, and monitor treatment effects, and has
been shown to accurately measure bone strength [20]. Each
finite element model consisted of eight-noded brick elements,
0.5 mm in length (approximately 1 million elements per mod-
el). Mechanical properties were derived from calibrated volu-
metric BMD values. The AGN1 volume of interest at the
immediate post-operative time point was simulated using
12-week images and registered to later time points. Within
the implant region, a scale factor (α) was applied assuming
either 100%, or conservatively, 30% of the new tissue per-
formed as normal load-bearing bone. As a conservative as-
sumption, non-resorbed high-density implant material was
assigned as minimal mechanical properties (Elastic modulus
= 10 MPa; Poisson’s Ratio = 0.3; and Ultimate Strength = 0.1
MPa). Boundary conditions were applied with the diaphysis
angled at 15° with respect to the ground and 15°of internal
rotation to simulate an unprotected fall to the side of the hip.
Femoral strength was defined from the non-linear force-strain
Table 1 Baseline demographic characteristics of study subjects
Characteristics Baseline (N = 12)
Age (years), mean (range) 71.7 (56–89)
Left femoral neck T-score, mean (SD) − 2.9 (0.4)
Right femoral neck T-score, mean (SD) − 2.9 (0.5)
Weight (kg), mean (SD) 53.5 (10.6)
Height (cm), mean (SD) 157.2 (5.4)
BMI (kg/m2), mean (SD) 21.6 (3.9)
Current osteoporosis medication use, N (%)
Bisphosphonate 6 (50%)
Hormone replacement therapy 1 (8%)
FRAX Calculated 10-year Risk*, mean (range)
Major osteoporotic fracture 19.8% (9.8–38%)
Hip fracture 8.6% (1.5–27%)
Comorbidities*, N (%)
Gastroesophageal reflux disease 5 (42%)
Chronic obstructive pulmonary disease 3 (25%)
Depression 3 (25%)
Hypertension 4 (33%)
Hyperlipidemia 3 (25%)
Coronary artery disease 1 (8%)
Osteoarthritis 6 (50%)
Rheumatoid arthritis 2 (17%)
Parkinson’s Disease 1 (8%)
Dementia 1 (8%)
*Retrospectively assessed at extended follow-up visit.
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curve as the force at 4.0% strain. Comparisons across all time
points were limited to those subjects who had complete data
from all three post-operative visits (9 subjects).
Statistical differences between treated and control hip
quantitative measures were tested using paired T-tests at each
time point.
Adverse events were evaluated and categorized according
to standard definitions by the investigators with the aid of an
independent study monitor. All adverse events were recorded
at the time of the procedure, at each visit throughout the 24-
month follow-up period, and at the 6-year follow-up visit. An
assessment of severity and relationship of causality to the
device and/or the procedure was performed. Medical history,
including the occurrence of any fragility fractures was record-
ed at each follow-up visit.
No subjects were lost to follow-up. All 12 subjects com-
pleted the 24-month follow-up visit and consented to the ad-
ditional extended follow-up visit. Ten subjects were available
for the imaging assessments at the extended follow-up visit.
The two subjects not available for the imaging assessments
completed medical history review.
Results
Subjects ranged in age from 56 to 89 years, with a mean of
71.7 ± 10.1 years (Table 1). Study subjects had low aBMD in
the proximal femur and their left treated and right control hips
did not differ in baseline aBMD (mean 0.527 ± 0.054 g/cm2
and 0.530 ± 0.045 g/cm2, respectively) or T-score (mean -2.9
± 0.4; range -2.2 to -3.4 and mean -2.9 ± 0.5; range -2.3 to -
4.1). Mean FRAX calculated 10-year risk of a hip fracture in
these subjects at the onset of the study was 8.6% (range from
1.5 to 27%). Subjects exhibited multiple comorbidities typical
of this age group, i.e., osteoarthritis, gastroesophageal reflux
disease, hypertension, and chronic obstructive pulmonary dis-
ease (Table 1).
Pre-treatment, X-ray (Fig. 2), and CT (Fig. 3) confirmed
the scarcity of trabecular bone in the proximal femur at base-
line. In all subjects, X-rays showed that the AGN1 implant
material within the intended enhancement site remained
where it was implanted in the proximal femur until it was
resorbed and replaced with bone (Fig. 2). AGN1’s initial uni-
form high density radiopacity concentrically changed to an
intermediate density as AGN1 resorbed. This change in size
and density was evident in both X-ray (Figure 2) and CT (Fig.
3) imaging as AGN1 was replaced with newly formed bone.
In the proximal femur, this newly formed bone was remodeled
and was still evident at the 5–7 year extension. In contrast,
AGN1 implant material that was initially within the medullary
canal of the femur of some subjects was resorbed and replaced
with mineralized tissue. However, by the 5–7 year follow-up,
this more distal mineralized tissue was no longer present (e.g.,
Subject 11, Fig. 3). X-ray analysis demonstrated that AGN1
was completely resorbed in 4 subjects by 24 weeks post-treat-
ment, and in all 10 subjects imaged at the 5–7 year extension.
CT confirmed these results. By 24 weeks, semi-quantitative
analysis of CT images demonstrated that only 17 ± 14% of
AGN1 remained with complete resorption by the extension
time point (see Supplemental Data Table 1).
All 12 subjects demonstrated a large immediate increase in
femoral neck aBMD at 1 week after AGN1 injection (Fig. 4).
This immediate increase remained significantly greater than
the corresponding control hips at all subsequent time points (p
< 0.0001). Specifically, the treated femoral neck aBMD was
68 ± 22% higher than the control at 12 months; 59 ± 24%
greater at 24 months; and 58 ± 27% higher at 5–7 years post-
treatment. From 1 to 24 weeks after treatment, there was a
rapid decrease in aBMD, which coincided with AGN1 resorp-
tion. After 24 weeks, there was a slower decrease in aBMD
that remained significantly elevated above untreated hips at all
individual time points through the 5–7 year follow-up.
Although not significant, femoral neck aBMD declined
1.2% and 1.4% from 24 months until the extended follow-
up visit in the treated hips and control hips, respectively.
Fig. 1 Fluoroscopic series showing key steps in AGN1 LOEP. a Insertion
of the guide pin to the apex of the femoral neck. b Cannulated drill
advancement over the guide pin to the subcapital epiphyseal scar. c
Gentle debridement to define the enhancement site followed by
irrigation to remove loose elements. d Injection of the implant material
to fill the enhancement site
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A consistent response was observed in all subjects. All re-
gions of the proximal femur showed a similar temporal pattern
of aBMD change as seen in the femoral neck ,i.e., an immediate
dramatic increase, a period of rapid decrease as AGN1 resorbed,
followed by a gradually declining steady state that remained
significantly greater than the control to the final time point. The
increase in aBMD following AGN1 LOEP treatment was the
same in patients who were or were not prescribed with anti-
resorptive therapy. Subject compliance with medication, howev-
er, was not captured. At no time point in any subject did the
treated hip aBMD in any region drop below that of the control
hip (Supplemental Data Tables 2 to 13).
All subjects exhibited large increase in femoral strength on
the treated side, as assessed by FEA simulating a sideways fall
configuration. Two sets of results are presented to provide
bounds on the expected in vivo behavior accounting for the
range in the biomechanical properties of the newly formed
mineralized tissue in the originally implanted region. Within
the implant region, a scale factor (α) was applied assuming
either 100%, or conservatively, 30% of the new tissue per-
formed as normal load-bearing bone. Regardless of the scale
factor used, femoral strength was significantly higher in the
treated compared with the contralateral control femur at 12
weeks, 24 weeks, and 5–7 years following the LOEP
Fig. 3 CT series from subject 06 (top row) and Subject 11 (bottom row) showing paucity of trabeculae in the femoral neck at baseline, and subsequent
formation and remodeling of new bone; left to right: Pre-treatment, Post-treatment 12weeks, 24 weeks, and at the extension follow-up average of 6 years
Fig. 2 Representative X-ray series from subject 07 showing AGN1 resorption and replacement with new bone in the proximal femur; left to right: pre-
treatment, post-treatment 12 weeks, 24 weeks, and 311 weeks
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procedure (p < 0.01; Table 2). At 12 weeks, hip strength was
on average higher in the treated versus control hip by 59% (α
= 1.00) or 41% (α = 0.30) (p < 0.01). At 24weeks, the average
hip strength was 54% (α = 1.00) or 37% (α = 0.30) (p < 0.01)
higher in the treated than control hip. At 5–7 years, the treat-
ment effect persisted as the strength of the treated femurs was
36% (α = 1.00) or 22% (α = 0.30) (p < 0.01) higher relative to
control femurs.
There were no procedure or device-related serious ad-
verse events and there were also no unanticipated adverse
events. Ten adverse events were reported in five subjects,
none of which were device-related (pneumonia, shoulder
pain, and squamous cell carcinoma). Three adverse events
were at least possibly related to the LOEP surgical proce-
dure (small area of wound breakdown, irritation from the
injection procedure, and post-operative nausea), which
were mild and resolved without additional medical inter-
vention. Seven osteoporosis-related fragility fractures
were observed: 2 control hips (27 and 44 months), 1 treat-
ed hip (40 months), 1 patella (8 months), 2 vertebrae (73
months and unknown), and 1 humerus (35 months)
(Table 3). One vertebral fracture at 12 months post-
treatment resulted from a motor vehicle accident was not
classified as a fragility fracture.
It is unlikely that detection bias contributed to the results
given no subjects were lost to follow-up and a review of med-
ical charts for all subjects to verify data was completed.
Discussion
This first-in-human study examined the potential utility of a
novel local osteo-enhancement procedure to improve hip bone
strength in postmenopausal women. A unique aspect of
AGN1 LOEP treatment is that it directly addresses osteopo-
rotic bone loss in the area treated. Moreover, AGN1 implant
material placement was similar to the optimal placement with-
in the femoral neck and intertrochanteric region as outlined by
Basafa et al. [21]. Accordingly, treatment with AGN1 LOEP
resulted in notable, statistically significant, and sustained in-
creases in proximal femur aBMD and these changes in aBMD
correlated with a substantial increase in femoral strength. In
particular, femoral neck aBMD in the treated hip was on av-
erage 58% greater and femoral strength was 36% greater than
the control hip at 5–7 years after treatment.
The time course of aBMD changes following LOEP can be
explained by the nature of the AGN1 material and its resorp-
tion profile. Notably, the AGN1 implant material has a high
radiopacity, thus explaining the immediate and large femoral
neck aBMD increase immediately after treatment. Thereafter,
as seen in the X-ray and CT analyses, the AGN1 is rapidly
resorbed, leading to a notable decrease in aBMD over the first
24 weeks. However, by 24 weeks AGN1 was substantially
resorbed and residual AGN1 contributed only minimally to
aBMD. AGN1 was completely resorbed and made no contri-
bution to aBMD from 1-year after treatment through the 5–7
year follow-up. Therefore, the sustained long-term increases
in aBMD and femoral strength were due to newly formed
bone and not to residual AGN1.
AGN1 resorption was closely coupled to new bone forma-
tion and the area of bone formation correlated with the area of
AGN1 implantation, i.e., the enhancement site of AGN1 in-
jection appeared to provide a template for bone formation. A
consistent treatment response was observed in all subjects,
with no discernable difference among subjects regarding
AGN1 resorption, aBMD and femoral strength changes after
AGN1 treatment, or changes in X-ray or CT images, despite
variable use of osteoporosis pharmacologic therapies by these
subjects. The consistency and magnitude of the increases in
femoral strength combined with the sustained nature of the
femoral strength gains through 5–7 years indicate that
AGN1 LOEP likely provides a long-term benefit to osteopo-
rotic subjects. In addition to the likely long-term benefit, a
prior study in human cadaveric femurs demonstrated that
Fig. 4 Femoral neck aBMD in treated and control hips as assessed by
DXA.N = 12 except at 315 weeksN = 10; p < 0.001 treated vs control for
all time points
Table 2 FEA-estimated femoral strength in sideways fall
Time point Control femur strength (N) Treated femur
strength (N)
Pre-treatment 2028 ± 469 2077 ± 469
Post-treatment α = 0.30a α = 1.00a
12 Weeks 1994 ± 425 2820 ± 463* 3165 ± 432*
24 Weeks 2013 ± 425 2755 ± 402* 3101 ± 392*
315 Weeks 1981 ± 338 2420 ± 396* 2685 ± 403*
a Scale factor (α) was applied to implant region assuming either 30% or
100% of the new tissue performed as normal load-bearing bone.
Statistical significance as assessed by paired t test indicated with *indi-
cates p < 0.01 when compared with the control at the same time point.
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AGN1 implantation also leads to an immediate increase in
femoral strength [18]. Although the sample size does not al-
low for a statistical assessment of fracture reduction, increased
aBMD and femoral strength via FEA correlates with bone
strength and fracture risk reduction [19, 20, 22, 23], suggest-
ing that AGN1 LOEP has the potential to reduce hip fracture
risk.
Several lines of evidence indicate that the newly formed
bone is functional with the characteristics necessary to re-
duce the risk of hip fracture by increasing the force needed
to fracture. First, the 1.2% decline in aBMD in the treated
hip from the 24-month to the 5–7-year follow-up is what
one would expect of ongoing bone turnover in these osteo-
porotic patients, i.e., the new bone is responding as one
would expect of existing bone in these patients. This obser-
vation is consistent with the assertion that increased density
in the implant area is due to newly formed bone that exhibits
features of normal bone metabolism. Second, both the X-ray
and CT analyses suggest that the newly formed bone ma-
tured and became integrated and incorporated into the sur-
rounding trabecular bone. This observation of bone matura-
tion and enhancement of structural integrity of the proximal
femur (Fig. 3) is supported by the absence of radiolucency
surrounding the area of new bone formation as well as the
presence of larger trabecular plates extending to and from
the newly formed bone and adjacent cortical bone. Third,
the evolution of the radiographic appearance of the newly
formed bone through the last time point suggests biologic
transformation of the bone through the final follow-up time
point. This is seen in density increases in portions of the
outer border of the implanted area related to bone formation,
while there was some diminution in the overall size of the
denser area from the 24-week to the average 6-year follow-
up interval. Note the 6-year CT images were performed on a
different CT scanner with higher spatial resolution (Fig. 3).
Fourth, newly formed bone tended to remain in areas that
were under mechanical stress, while resorbing from areas of
minimal stress (Fig.3), such as the medullary canal, again
consistent with normal bone metabolism. Finally, the
subject-specific FEA demonstrated substantial improvement
in femoral strength at all follow-up time points.
There is ample evidence for a strong correlation between
aBMD of the proximal femur and hip fracture risk [8, 22]. For
example, in the HORIZON Recurrent Fracture Trial, which
tested whether zoledronic acid would prevent contralateral hip
fractures in those who had already suffered one hip fracture,
modest increases in femoral neck aBMD (3.6% over 3 years)
led to a clinically meaningful and significant 30% decrease in
the incidence of hip fractures [24]. Similarly, strong correla-
tions have been demonstrated between FEA-estimated hip
strength and hip fracture risk [19, 20]. For example,
denosumab treatment increased FEA-estimated hip strength
9% relative to baseline at 36months [25], which corresponded
to an observed hip fracture reduction of 42% [26].
Comparatively speaking, AGN1 LOEP treatment resulted in
a sustained 58% average BMD increase and 36% increase in
FEA-estimated hip strength after 5–7 years. These results sug-
gest that AGN1 LOEP has the potential to dramatically reduce
fracture risk with a single treatment.
Hip fracture risk reduction with existing drug therapies is
achieved only when patients are compliant and persistent with
treatment. However, less than 35% of patients continue with
osteoporosis therapy at 1 year [12, 27]. Real-world hip frac-
ture prevention with drug therapy is further limited due to
under-diagnosis of osteoporosis, limited prescription of phar-
maceutical therapies to osteoporotic patients, delayed onset of
effectiveness of these therapies, and an incomplete 30 to 51%
hip fracture risk reduction [11, 24, 26, 28]. In contrast, AGN1
LOEP provides immediate [18] and as noted above, long-term
protection, and compliance is guaranteed as the treatment is a
one-time procedure. Moreover, the AGN1 LOEP treatment
response was observed in all subjects whether or not they were
taking anti-resorptive drugs, demonstrating the feasibility of
using AGN1 LOEP in patients on systemic osteoporosis
therapy.
Like osteoporosis medicat ions and other non-
pharmacologic means of managing hip fracture risk (i.e., life-
style changes), the AGN1 LOEP treatment is expected to sig-
nificantly reduce, but not eliminate, the risk of fragility hip
fractures. Two control hips (2 of 12, 16.6%) and one treated
hip (1 of 12, 8.3%) fractured during the 72 patients’ years of
follow-up (Table 3). The fracture of the AGN1 LOEP treated
Table 3 Summary of all fragility
fractures Subject Fracture location Time post-procedure Age at fracture Cause
02 Left proximal humerus 36 months 83 Fall
03 Left patella 8 months 87 Fall
Left hip (treated) 40 months 90 Unknown
Right hip (control) 44 months 90 Fall
Spine (level unknown) 73 months 93 Unknown
05 Right hip (control) 27 months 67 Fall
08 Spine (T8) Unknown Unknown Unknown
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femur was a subcapital fracture that was successfully repaired
by hemiarthroplasty without complication. The treated hip
fracture occurred in Subject 03 (Table 3) with the most fragil-
ity fractures and the greatest number of risk factors for a hip
fracture including advanced age (90 years), Parkinson’s dis-
ease, dementia, stroke, and COPD.
Past efforts to locally strengthen the proximal femur, and
thereby reduce the risk of hip fracture, generally focused on
the implantation of inert, permanent materials (e.g. PMMA)
[16, 29–32]. In contrast, this is a biological approach to locally
strengthen the proximal femur by replacing bone lost due to
osteoporosis. As a single-center 12 subject study, the experi-
ence and conclusions from this study may not be generalizable
to the broader population; however, the results are promising
and support the potential clinical utility of this new treatment.
The safety profile of this treatment observed in this study is
consistent with other minimally-invasive orthopedic proce-
dures (e.g., femoral head core decompression). This study
supports the safety of this minimally-invasive surgical inter-
vention as a new approach to treat osteoporotic bone loss and
reduce hip fracture risk.
In conclusion, this first-in-human study establishes AGN1
LOEP as an emerging treatment for local osteoporotic bone
loss in patients at high risk of hip fracture and provides strong
rationale for further clinical investigation of this treatment.
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